Drug Type Diagnostic radiopharmaceuticals |
Synonyms [18F]-FPyQCP |
Target- |
Action enhancers |
Mechanism PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Colorectal Cancer | Phase 2 | United States | 31 Jan 2026 | |
| Invasive Lobular Breast Carcinoma | Phase 2 | United States | 31 Jan 2026 | |
| Ovarian Epithelial Carcinoma | Phase 2 | United States | 31 Jan 2026 | |
| Pancreatic Ductal Adenocarcinoma | Phase 2 | United States | 31 Jan 2026 | |
| Stomach Cancer | Phase 2 | United States | 31 Jan 2026 |





